Table 5. Prior Studies of PTCL... | American Society of Hematology

Table 5.

Prior Studies of PTCL

Institution	No. of Patients^5-150	Median Age (yr)	AA Stage 3 or 4 (%)	B Symptom (%)	CR Rate (%)	5-yr OS (%)	Ref
Vanderbilt	33	64	79	67	24^5-151	<10	14
Arizona	20	59	80	60	50	40	11
Netherlands	20	57	60	—	—	27	4
Stanford	21	<50	18	29	95	78	5
Austria	38	54	—	—	37	<40	10
Nebraska	80	57	72	57	50	40	9
France	108	—	77	58	72	45	2
M.D. Anderson	68	54	78	56	75	39
Total	360	52-57	65-75	55-60	50-70	30-50

Institution	No. of Patients^5-150	Median Age (yr)	AA Stage 3 or 4 (%)	B Symptom (%)	CR Rate (%)	5-yr OS (%)	Ref
Vanderbilt	33	64	79	67	24^5-151	<10	14
Arizona	20	59	80	60	50	40	11
Netherlands	20	57	60	—	—	27	4
Stanford	21	<50	18	29	95	78	5
Austria	38	54	—	—	37	<40	10
Nebraska	80	57	72	57	50	40	9
France	108	—	77	58	72	45	2
M.D. Anderson	68	54	78	56	75	39
Total	360	52-57	65-75	55-60	50-70	30-50

Patients with intermediate-grade histology and receiving combination chemotherapy only.

Not all had an anthracycline-containing regimen.